In situ photoimmunotherapy for melanoma: an ongoing phase I clinical trial

Mark F. Naylor; Robert E. Nordquist; T. Kent Teague; Lisa A. Perry; Wei R. Chen

doi:10.1117/12.711217

13 February 2007 In situ photoimmunotherapy for melanoma: an ongoing phase I clinical trial

Mark F. Naylor, Robert E. Nordquist, T. Kent Teague, Lisa A. Perry, Wei R. Chen

Proceedings Volume 6438, Biophotonics and Immune Responses II; 643807 (2007) https://doi.org/10.1117/12.711217
Event: SPIE BiOS, 2007, San Jose, California, United States

Abstract

In situ Photoimmunotherapy (ISPI) was developed to treat metastatic tumors using a combination of phototherapy and immunotherapy. It utilizes local intervention through photothermal destruction of existing solid tumors and through immune response modifier to elicit host anti-tumor responses. Such combination in pre-clinical studies has shown promise in cancer treatment by eradicating the primary tumors and also controlling metastases at distant sites. ISPI has been used in our preliminary clinical studies for melanoma patients and the outcome has been extremely encouraging. In 2006, we began enrolling patients in a new phase I immunotherapy trial for advanced cutaneous melanoma. This trial is based on our previous results which indicated that we had developed an effective treatment for advanced melanoma. Of the first six patients treated, (4 stage IV, and 2 surgically unresectable stage III), 2 of the stage IV patients are still alive, one tumor free, and one with a possible treatable recurrence after 2 1/2 years. We have also discovered that recurrences of the skin cancer can be retreated by the same technique and that treatment seems to blunt the virulence of the disease and make it more treatable. These initial results indicate that ISPI probably will have the ability to prolong survival in selected cases of advanced melanoma, and potentially cure a significant percentage of treated patients.

Citation Download Citation

Mark F. Naylor, Robert E. Nordquist, T. Kent Teague, Lisa A. Perry, and Wei R. Chen "In situ photoimmunotherapy for melanoma: an ongoing phase I clinical trial", Proc. SPIE 6438, Biophotonics and Immune Responses II, 643807 (13 February 2007); https://doi.org/10.1117/12.711217

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available